Search

Prasugrel

Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary … Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727.

Sodium phosphate, dibasic, unspecified form

Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated)

Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) is a vaccine that contains inactivated acellular pertussis antigen that is isolated from Bordetella pertussis culture.

Pariglasgene brecaparvovec

Pariglasgene brecaparvovec-opnr is an adeno-associated virus serotype 8 (AAV8)–based gene therapy for glycogen storage disease type Ia (GSDIa), a disorder caused by deficiency of the enzyme glucose-6-phosphatase … [L64050] The FDA granted pariglasgene brecaparvovec-opnr accelerated approval on August 19, 2026, making it the first approved treatment for glycogen storage disease type Ia.

Desmopressin

On January 15, 2026, the FDA approved a new low-dose sublingual film formulation specifically for the treatment of nocturia in patients at high risk for fluid overload, utilizing a specialized delivery … First synthesized in the 1960s, desmopressin has remained a gold-standard therapy for water balance disorders due to its safety and long duration of action compared to natural AVP [A31661, A275461].

Palonosetron

It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of … Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).

Ozanimod

[A189336] In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard … Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease.

Polycarbophil

It is insoluble in water, dilute acids, and dilute alkali. … Polycarbophil calcium is a stool stabilizer used to treat constipation. This drug may also be used to help relieve the symptoms of irritable bowel syndrome or diarrhea.

Pimavanserin

Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. … [A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized

Calcium glycerophosphate

By FDA, calcium glycerophosphate is considered a generally recognized as safe (GRAS) food ingredient as a nutrient supplement (source of calcium or phosphorus), or in food products such as gelatins, puddings … It is also present in dental or oral hygiene products due to its cariostatic effects.